Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN-D0501 in Type 2 Diabetes Mellitus
NCT03278158Phase 2Completed
- Sponsor
- Pila Pharma
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of XEN-D0501 in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Pila Pharma. Primary endpoint: Incidence of adverse events. Started Sep 2017; status: completed.
02
Drugs
XEN-D0501
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03278158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278158.